The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world.
In addition, this edition includes summary and recommendations from the virtual meeting of the members of the WHO Programme f...or International Drug Monitoring (PIDM) and other partners, which was held on 20 October 2022.
more
Assessment in action series
Key Findings from Azerbaijan, Georgia, Kyrgyzstan, Russia, and Ukraine
Writing by Katya Burns
Editing by Paul Silva and Roxanne Saucier
Q&A on COVID-19, HIV and antiretrovirals - Hỏi Đáp về COVID-19, HIV và thuốc antiretrovirals (ARVs)
This guidance document sets out a methodology to identify and track financing to the WASH sector in a coherent and consistent manner across several countries. It is designed to help countries track financing to the WASH sector on a regular and comparable basis and analyse this information to support... evidence-based policy-making based on useful indicators.
more
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi...th severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.
more
2nd edition - Published in 2003, the first WHO/HAI medicine prices manual Medicine Prices – A
New Approach to Measurement Draft for field-testing provides a draft methodology and tools to conduct national medicine prices and availability surveys. This second edition of the survey manual has been... updated to reflect the wealth of practical
experience in conducting medicine prices and availability surveys garnered in the project’s first two phases.
more
Le présent document est une mise à jour du document d’information scientifique publié le 29 mars 2020 intitulé Modes of transmission of virus causing COVID-19: implications for infection prevention and control (IPC) precaution recommendations et comprend les nouvelles don...nées scientifiques disponibles sur la transmission du SARS-COV-2, le virus responsable de la COVID-19.
more
Guidance module.
The QualityRights training and orientation modules have been developed to enhance the knowledge, skills and understanding of key stakeholders on how to promote the rights of people with psychosocial, intellectual or cognitive disabilities, improve the quality of services and suppo...rt provided in the field of mental health and related areas, in line with international human rights standards, in particular the UN Convention on the Rights of Persons with Disabilities and the recovery approach.
mental health and related fields, in accordance with international human rights standards, in particular the UN Convention on the Rights of Persons with Disabilities and the recovery approach.
more
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these... or other herbal medicines; and
• facilitate information exchange among Member States.
more
Noncommunicable diseases (NCDs) such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Kyrgyzstan. This report provides evidence through three analyses that NCDs reduce economic outp...ut and discusses potential options in response, outlining details of their relative returns on investment. An economic burden analysis shows that economic losses from NCDs are equivalent to 3.9% of gross domestic product. An intervention costing analysis provides an estimate of the funding required to implement a set of policy interventions for prevention and clinical interventions. A cost–benefit analysis compares these implementation costs with the estimated health gains and identifies which policy packages would give the greatest returns on investment.
more
This document serves to provide interim guidance/ recommendations to carry out mpox surveillance activities mainly case investigation, contact tracing and isolation. For the development of this document WHO, UKHSA and CDC guidelines were referred to and adopted within the country context.